ReviewmAbs2026
Targeted dual selection to optimize transposon stable pool generation of multispecifics.
Review in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Challenges and solutions for upstream processing of complex biologics.Antibody therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growing knowledge around disease states has led to opportunities within research to make designer molecules with improved specificity and broader efficacy. These next-generation molecules frequently take advantage of multispecific targeting and controlled mechanisms of action by utilizing four unique peptide chains as seen in many bispecific or trispecific antibodies. However, with all the opportunities these multispecifics offer, their increased biological complexities come with increased challenges during expression and purification to produce high-quality material. Lower yields accompanied with a high degree of mispairing after the initial capture purification step are often limiting factors. Developing new methods for stable pool expression can offer a strong advantage for progressing these molecules through research toward development. Here, we implemented optimized stable cell pools using targeted dual selection (TDS), a novel approach that combines specified selective pressure with transposon-guided semi-targeted gene integration. By utilizing key analytical data obtained during early-stage high-throughput transient productions, we can predict improved vector configurations for the generation of optimized TDS stable pools. We demonstrate that this design can improve molecule quality at the initial capture purification step in two Y-shaped bispecific molecules and two cross-over dual variable trispecific molecules by achieving up to four-fold increase in protein of interest yields while maintaining product quality. Use of this strategy in research can enable simplified purification strategies as well as increased production yields required for successful and timely project progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.